Kamada Ltd (KMDA) stock

KMDANasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 11, 2026Score 5/30

$8.09−0.04 (-0.49%)

Close on Nov 13, 2026Market cap $466.68MP/E –Yield –

Kamada r&d expenses

Research and development expenses are spending on new products and technology.

Kamada's R&D Expenses for the twelve months ending Jun 30, 2026 was $9.91M, down 26.9% year over year. For fiscal 2025 it was $13.00M, down 14.4% from the year before. Over ten years it grew -2.4% a year on average. The highest annual figure on record is $16.53M in fiscal 2015.

Annual r&d expenses

Period	Period end	Value	Change
FY2025	Dec 31, 2025	$13.00M	-14.4%
FY2024	Dec 31, 2024	$15.19M	+9.0%
FY2023	Dec 31, 2023	$13.93M	+5.8%
FY2022	Dec 31, 2022	$13.17M	+16.0%
FY2021	Dec 31, 2021	$11.36M	-16.5%
FY2020	Dec 31, 2020	$13.61M	+4.2%
FY2019	Dec 31, 2019	$13.06M	+34.0%
FY2018	Dec 31, 2018	$9.75M	-18.6%
FY2017	Dec 31, 2017	$11.97M	-26.3%
FY2016	Dec 31, 2016	$16.25M	-1.7%
FY2015	Dec 31, 2015	$16.53M	–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

Period	Period end	Value	Change
Q2 FY2026	Jun 30, 2026	$2.20M	-31.7%
Q1 FY2026	Mar 31, 2026	$2.18M	-48.6%
Q4 FY2025	Dec 31, 2025	$2.89M	+8.3%
Q3 FY2025	Sep 30, 2025	$2.64M	-22.8%
Q2 FY2025	Jun 30, 2025	$3.22M	-33.0%
Q1 FY2025	Mar 31, 2025	$4.25M	-1.1%
Q4 FY2024	Dec 31, 2024	$2.67M	-17.5%
Q3 FY2024	Sep 30, 2024	$3.41M	+7.4%
Q2 FY2024	Jun 30, 2024	$4.80M	+12.1%
Q1 FY2024	Mar 31, 2024	$4.30M	+132831.0%
Q4 FY2023	Dec 31, 2023	$3.24M	-75.4%
Q3 FY2023	Sep 30, 2023	$3.18M	+101888.5%
Q2 FY2023	Jun 30, 2023	$4.28M	+62.1%
Q1 FY2023	Mar 31, 2023	$3.23K	-99.9%
Q4 FY2022	Dec 31, 2022	$13.16M	+281.7%
Q3 FY2022	Sep 30, 2022	$3.12K	-99.9%
Q2 FY2022	Jun 30, 2022	$2.64M	-3.4%
Q1 FY2022	Mar 31, 2022	$4.42M	+35.0%
Q4 FY2021	Dec 31, 2021	$3.45M	+2.5%
Q3 FY2021	Sep 30, 2021	$2.55M	–
Q2 FY2021	Jun 30, 2021	$2.74M	–
Q4 FY2020	Dec 31, 2020	$3.27M	–
Q3 FY2020	Sep 30, 2020	$3.37M	–